<DOC>
	<DOCNO>NCT00840775</DOCNO>
	<brief_summary>The purpose study collect analyze additional information safety effectiveness Presillion™ Stent System treatment de novo stenotic lesion native coronary artery .</brief_summary>
	<brief_title>PIONIR Study ( Presillion™ Presillion™ Plus Stent Systems )</brief_title>
	<detailed_description>This post market , non-randomized , multi-center , prospective , single arm clinical study conduct 25 site Europe Israel . All patient follow 30 day , 6 month , 9 month 1 year post index stenting procedure . The primary endpoint incidence target vessel failure ( TVF , see definition ) within 270 day treatment Presillion™ Stent System . This rate compare performance goal derive use meta-analysis standard-of-care therapy , coronary stenting bare metal stent . This data use support PMA application Presillion™ Stent System .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1 . Patient &gt; = 18 year old . 2 . Eligible Percutaneous Coronary Intervention ( PCI ) . 3 . Patient understands nature procedure provide write informed consent prior catheterization procedure . 4 . Patient willing comply specify followup evaluation contact telephone . 5 . Acceptable candidate coronary artery bypass graft ( CABG ) surgery . 6 . Stable angina pectoris ( Canadian Cardiovascular Society ( CCS ) 1 , 2 , 3 4 ) unstable angina pectoris ( Braunwald Class 13 , BC ) positive functional ischemia study ( e.g. , ETT , SPECT , Stress echocardiography Cardiac CT ) . 7 . Male nonpregnant female patient ( Note : female child bear potential must negative pregnancy test prior enrollment study ) . 1 . Currently enrol another investigational device drug trial complete primary endpoint clinically interfere current study endpoint . 2 . Previously enrol another stent trial previous 2 year . 3 . ANY plan elective surgery percutaneous intervention within subsequent 9 month . 4 . A previous coronary interventional procedure kind within 30 day prior procedure . 5 . The subject require staged procedure either target nontarget vessel within 9 month postprocedure . 6 . Previous drug elute stent ( DES ) deployment anywhere target vessel . 7 . Any drug elute stent ( DES ) deployment anywhere within past 12 month 8 . Comorbid condition ( ) could limit patient 's ability participate trial comply followup requirement , impact scientific integrity trial . 9 . Concurrent medical condition life expectancy le 12 month . 10 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , L605 Cobalt chromium alloy sensitivity contrast medium , adequately premedicated .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Stent</keyword>
	<keyword>interventional cardiology</keyword>
	<keyword>catheterization</keyword>
	<keyword>symptomatic ischemic heart disease</keyword>
</DOC>